Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Current opinion in investigational drugs (London, England : 2000) (2007-03-03)

Alan P Johnson

摘要

Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.

材料

货号

品牌

产品描述

SML1750

Sigma-Aldrich

Fidaxomicin, ≥95% (HPLC)